A Nevada bill targets drug makers over price hikes, but only for diabetes meds

first_img By Ed Silverman March 30, 2017 Reprints Log In | Learn More About the Author Reprints What’s included? Pharmalot GET STARTED What is it? [email protected] A Nevada lawmaker has introduced a bill to fight the rising cost of medicines, one of dozens state legislators to attempt such a move. But this one has a twist — the legislation targets only companies that make diabetes drugs and insulin.Specifically, the bill requires drug makers to report pricing histories; disclose a slew of costs, such as research, manufacturing, and patient assistance; and notify state officials and insurers at least 90 days before prices are increased above the inflation rate for the preceding year. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTEDcenter_img Tags drug pricingpharmaceuticalsSTAT+ @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. A Nevada bill targets drug makers over price hikes, but only for diabetes meds Insulin bottles at a Novo Nordisk factory in France. Francois Monier/AFP/Getty Images Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.last_img

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*